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Abstract
Background
Hepatitis B virus (HBV) predominantly spreads through contact with infected blood or other body fluids and causes liver disease. HBV vaccination 
for students at the College of  Medicine, University of  Malawi, is done without screening for the virus. It is important to assess the prevalence of  HBV 
antigens among foundation-year students in order to consolidate evidence in support of  HBV screening before vaccination.
The aim of  this study was to determine the seroprevalence of  HBV antigens among 2013-2014 foundation-year students at the University of  Malawi 
College of  Medicine.
Methods
A prospective cross-sectional descriptive study was conducted among 2013-2014 foundation year students at the Malawi College of  Medicine. Out of  
the 234 foundation-year students, written consent was obtained from 89 students. Venous blood samples were collected and tested for HBV surface 
antigen using SD Bioline immunochromatographic rapid assays.
Results
Out of  the 62 (69.7%) male students, none tested HBV-positive, and out of  27 (30.3%) female students, none were seropositive. This suggested the 
absence of  HBsAg among students or presence of  HBsAg levels below detectable limits.
Conclusions
This study showed levels of  HBsAg below detectable limits among healthy young adults in Malawi. HBV screening for medical students should further 
be assessed to ensure adequate protection before they are assigned clinical duties. These findings provide enough grounds to agitate for further surveys 
to support the establishment of  a universal HBV immunisation programme in Malawi.
Introduction
Hepatitis B virus (HBV) is a partially double-stranded (ds) 
deoxyribonucleic acid (DNA) virus, which can potentially 
cause liver disease that may progress to chronic hepatitis, 
cirrhosis, and hepatocellular carcinoma.1,2 According to the 
World Health Organization (WHO), about a third of  the 
global population is infected with HBV, with an estimated 240 
million people living with chronic HBV and approximately 
780,000 HBV-attributable deaths reported annually.3 HBV is 
ubiquitous, but high prevalence rates are reported in sub-
Saharan Africa (10 to 20%),4 compared to the developed world 
(0.2 to 0.5%).5 HBV remains an occupational health hazard; 
therefore, assessment of  the magnitude of  pre-exposure 
and possible infection among Malawian medical students 
doing clinical placements in public hospitals in Malawi is 
pertinent. The Malawi Ministry of  Health recommends 
immunisation of  medical students and healthcare workers 
before they come in contact with patients at all levels, but 
adherence to and enforcement of  such recommendations 
has been inconsistent. Healthcare personnel, including 
medical students, are at risk of  occupational exposures, such 
as HBV and other blood-borne viruses, through needlestick 
injuries and contact with infected blood or blood products.6 
Likewise, uninfected hospitalised patients are at risk of  HBV 
exposure from infected healthcare workers. Therefore, HBV 
vaccination either pre- or post-screening is recommended 
among medical students and other healthcare workers.
In 1991, the WHO recommended that all countries introduce 
universal HBV immunisation policies. Countries such as 
Taiwan (1984), Italy, Spain and the United States of  America 
(1991), and Israel (1992) were some of  the early adopters 
of  HBV universal immunisation.8 Subsequently, global HBV 
immunisation coverage increased from < 1% in 1990 to 60% 
in 2006.7 Malawi adopted the HBV universal vaccination 
programme in 2002. 
HBV diagnosis is done by performing serological assays to 
detect different viral markers, biochemical investigations 
to assess the hepatic injury, molecular techniques to detect 
genetic markers, and liver biopsy, amongst others.9,10 In 
Malawi, screening for hepatitis B virus surface antigen 
(HBsAg) in public hospitals and health centres is done by 
rapid immunochromatographic diagnostic test (RDT) kits 
that are readily available at the point of  care or in laboratories. 
There are no contemporary published data regarding the 
national HBV prevalence among medical students in Malawi. 
However, few data for HBV screening among small targeted 
populations exist. Previous research revealed a 7.6% HBV 
prevalence among blood donors, and an estimated 9.5% 
HBV prevalence among hospitalised patients without 
observable liver disease.11 The HBV prevalence rate among 
blood donors in Ntcheu District, Malawi, has been reported 
to be about 8.1%.12 Estimates of  HBV prevalence amongst 
healthy young adults in Africa vary greatly. A 15.5% HBsAg 
prevalence has been reported among high school and 
university students.13 Such high HBV prevalence estimations 
reflect substantial risk to healthcare workers.
RDTs are accurate for HBsAg screening purposes.2,3 Public 
referral hospitals and other health institutions perform 
additional supplementary or confirmatory laboratory testing 
for the  presence or absence of  HBV biomarkers.
The aim of  this study was to estimate the epidemiology and 
seroprevalence of  HBsAg among medical students at the 
University of  Malawi.
Methods
This quantitative descriptive cross-sectional study was 
conducted at the College of  Medicine (COM), University of  
Malawi, Blantyre, in 2013. The study population comprised 
all foundation-year (premedical) students. The optimal 
sample size to detect statistical significance was estimated 
at 89 students, calculated using Epi-info version 3.5, with a 
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Malawi. The available HBV prevalence rates vary depending 
on HBV/HIV coinfection and between risk groups, such 
as pregnant women and hospital inpatients, among others. 
Our recommendations for HBV pre-screening concur with 
conclusions drawn from other studies carried out in Africa. 
Fritzsche et al. recommended that HBV screening should 
always be done among healthcare workers in Cameroon 
prior to vaccination.15 A similar study conducted on medical 
students at Makerere University in Uganda concluded that 
medical students should be offered more HBV sensitisation 
and prevention information, as well as public health 
interventions, including universal precautions for infection 
control.16
Utilisation of  different testing methods to detect multiple 
biomarkers improves the power estimation for HBV infection. 
Demographic and geographic differences that could 
determine the risks of  exposure among different populations 
also influence the varying prevalence rates determined in 
different regions of  Africa and the rest of  the world. Our 
findings suggest that there was a low prevalence of  hepatitis 
B virus in the study population. These results are different 
from previous studies conducted on medical inpatients in 
Malawi, where HBsAg prevalence was estimated at 38% using 
point-of-care testing, and 17.5% after confirmatory assays 
were performed at reference laboratories outside Malawi. 
Our prevalence findings also differ from those of  the study 
conducted at Makerere University, where an overall HBsAg 
prevalence of  11.0% and anti-HBc prevalence of  65.9% 
were reported.16 Similar research carried out at Lagos State 
University College of  Medicine, in Nigeria, reported a 3.2% 
HBsAg prevalence and a prevalence of  17.9% for anti-HBs 
antibodies among medical students at that institution.17 An 
HBV prevalence of  48% was reported among preclinical and 
clinical medical students in the United Arab Emirates;. half  
of  the students tested had prior immunisation at childhood 
but were reported to be susceptible to HBV infection.19 A 
study carried out at the University of  Malaya, in Malaysia, 
found a 0.62% HBV infection prevalence among medical 
students; that study used automated diagnostic assays to 
detect HBsAg, anti-HBs, and anti-HBc biomarkers.20
There continues to be vigorous campaigns by government, 
nongovernmental organisations (NGOs), and private 
institutions to sensitise the public against HIV infection in 
Malawi. Such awareness campaigns could also have a bearing 
on the reduction of  HBV exposure and subsequent infection 
among medical students.
Over the years, blood transfusion in Malawi has presumably 
been safe, after the establishment of  the Malawi Blood 
Transfusion Service (MBTS), whose overall objective is to 
supply safe blood and blood products in order to reduce the 
incidence of  HIV and other blood-borne infections. The 
absence of  HBV antigens reported in this study could either 
reflect a true low prevalence or low HBV viral load below 
detectable limits. HBsAg is the early marker detected in 
acute HBV infection. A combination of  HBV testing assays 
targeting different biomarkers would be ideal for conclusive 
HBV prevalence results. Anti-hepatitis B core (Anti-HBc) 
IgM antibodies are early biomarkers in acute HBV infection, 
produced in response to the core HBV antigen and persist for 
life, suggesting a past horizontal transmission in childhood 
and adulthood.21 Detection of  HBV DNA could be useful 
in establishing HBV infection, but the technique is obviously 
expensive and less appropriate in resource-limited settings. 
Therefore, confounding factors contributing to a low HBV 
prevalence cannot be ruled out in our findings. The use of  
external control samples (both positive and negative) offered 
an in-house validation of  the results.
On the whole, our findings require further investigations 
to establish if  the low undetectable levels of  HBVsAg 
confidence interval of  95%, an estimated frequency of  10%, 
and a worst acceptance value of  5%. Out of  234 premedical 
students who were enrolled in all COM programmes at 
the time of  data collection, 89 unvaccinated students 
were recruited into this study. The study was approved by 
the College of  Medicine Research and Ethics Committee 
(COMREC). Written consent was obtained from all study 
participants. Anonymisation of  study participants’ personal 
information and adherence to confidentiality standards was 
performed in compliance with COMREC guidelines.
Samples were collected, processed, and tested following 
detailed standard operating procedures (SOPs), as provided 
by the test kit manufacturer. Results were interpreted 20 
minutes after addition of  samples on test strips. HBV-
positive samples were provided by the serology division 
of  the Queen Elizabeth Central Hospital Laboratory in 
Blantyre. Both sensitivity and specificity of  the test kits 
was greater than 99%, with a detection limit of  2 ng/mL 
(meaning that a positive result indicated the presence of  ≥ 
2 ng/mL of  HBsAg), as indicated on the manufacturer’s 
instruction leaflet.
Results
Out of  the 89 consenting participants, 62 (69.70%) were 
males (Table 1). All 89 study participants were HBsAg 
seronegative, representing 100% seronegativity among the 
the study particpants (Table 1).
There were no negative or invalid (absence of  both test and 
control bands in the results window of  a test strip) results in 
this study.Table 1: Hepatitis B surface antigen (HBsAg) 




Positive QC Positive Negative
Negative QC Negative Negative
Males None 62 (69.70%)
Females None 27 (30.30%)
Total None 89 (100%)
Summary of HBV HBsAg serum testing results using BIOLINE HBsAg one-step 
immunochromatographic rapid test kit batch number 008283. All study samples 
showed negative or low HBVsAg levels below the detectable limit. 
QC = quality control
Discussion
This study included University of  Malawi College of  
Medicine premedical students from all regions of  the 
country. The HBV screening results suggest either an 
absence or low (undetectable) levels of  HBV surface antigen 
in the study population. The rapid serological diagnostic 
assay was chosen because it was the same one used in public 
health facilities in Malawi for HBV biomarker screening. 
The rapid test kits are highly sensitive and specific, do not 
require robust equipment or highly skilled labour, and they 
can be stored at ambient temperature.14 HBV vaccination 
is recommended for medical students at the University of  
Malawi, but HBV pre-screening is not routinely performed 
for all students who receive the HBV vaccine prior to clinical 
placements in public hospitals.
There are no contemporary published data about HBV 
prevalence among medical students and healthcare workers in 
Table 1: Hepatitis B surface antigen (HBsAg) seroprevalence test 
res lts for University of Malawi foundation year students
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among medical students reported in this study attest to the 
utility of  the universal HBV immunisation policy against 
HBV infection introduced in 2002 by the government of  
Malawi. HBV prevalence is high in sub-Saharan Africa,22 
therefore healthcare workers, including clinical medical 
students, are at particular risk of  exposure, particularly 
in areas of  high endemicity.23–26 The implementation of  
appropriate vaccination programmes would reduce the 
risk of  HBV infection among risk groups and those not 
suffering underlying chronic HBV infection.27 Vaccination 
programmes for undergraduate students enrolled at the 
University of  Malawi, as well as the vigorous implementation 
of  a universal immunisation programme, focusing on 
adolescents and the provision of  maternal prophylaxis to limit 
infant transmission, would help reduce HBV infection rates. 
Despite the small sample size investigated, these findings 
will provide part of  the baseline for future research work 
that could describe the epidemiology and seroprevalence of  
HBV among future healthcare workers and clinicians. The 
findings are not concordant with the available published data 
in Malawi and other parts of  Africa. Therefore, this calls for 
further studies and comprehensive systematic reviews.
Conclusions
This study, the first performed in a sub-population of  medical 
students in Malawi, suggests low levels of  HBV exposure. 
The study findings suggest that there is little evidence to 
encourage preclinical HBV screening of  medical students at 
the Malawi College of  Medicine before vaccination. Thus, 
despite study limitations that included time, small sample 
size, lack of  confirmatory tests, and financial constraints, the 
study provides important baseline information, which forms 
part of  the nationwide assessment of  HBV prevalence, and 
informs the universal immunisation policy. Other reports 
indicated high HBV prevalence rates in the country, which 
suggests that a significant proportion of  the population are 
susceptible to HBV infection. Therefore, HBV screening 
for medical students should further be assessed to ensure 
adequate protection before they are assigned clinical duties.
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